Gnosis Bio has demonstrated the ability to silence genes in the brain, heart, lung, muscle, kidney, and small intestine.

Gnosis Bio's platform is approximately 80% cheaper and three times faster for developing targeted gene silencing medicines compared to traditional methods.

Jim Martineau predicts that within five years, the term 'undruggable' will be eliminated from the pharmaceutical lexicon due to AI's ability to design molecules for any target.

Gnosis Bio has public collaborations with Johnson & Johnson, Daiichi Sankyo, and other top 10 global biopharma companies.

Over the last five years, the success rate for building a drug delivery system at Gnosis Bio has improved from one in a trillion to a 10-30% success rate due to its AI platform.

Gnosis Bio has raised more capital from pharmaceutical partnerships than from traditional venture capital investors.

Existing gene silencing medicines on the market have a clinical trial success rate of approximately 70%, compared to a 95% failure rate for many traditional medicines.

Avidity Bio was recently acquired for $12 billion for its technology that delivers gene silencing therapies to skeletal muscle.

The FDA is working on creating safety-guaranteed models for certain classes of drugs like monoclonal antibodies, which could eliminate the need for some safety trials.